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ABSTRACT 
In an exercise carried out to ascertain adequacy of antidepressant treatment, seventy case 
notes of patients of depression on continuation treatment with antidepressants were scanned. 
Antidepressants had been used universally. TCAs were the most commonly used drugs, although 
Fluoxetine had also been used quite frequently. Continuation treatment was found to be deficient in 
over a third (n=24; 34 %) of the cases, on either of the two parameters i. e. dose of drugs or duration 
of treatment. The outcome was poorer in those treated inadequately. The reasons for this 'treatment 
gap' need to be explored. Similar studies need to be conducted in other settings. Education of all 
clinicians about these central issues of antidepressant treatment is essential. 
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Two aspects of long term treatment with 
antidepressants are relapse prevention during a 
continuation treatment period in responders to 
acute treatment, and maintenance treatment for 
those who have remained well during the 
continuation phase, to prevent new episodes 
(Montgomery, 1994) Relapse prevention studies 
have shown that premature discontinuation of 
antidepressant treatment soon after response to 
treatment of the acute episode is associated with 
return of original symptoms in approximately half 
of the patients (Pnen & Kupfer, 1986). The 
continuation phase of treatment is thus required 
for consolidation of apparent response to 
antidepressants, and prevent early relapses. 
Two central issues in continuation therapy 
are duration of treatment and doses of the 
antidepressants to be used Regarding the former 
the unanimous conclusion is that all episodes of 
depression, whether first onset or recurrent, should 
be treated for a further period of about six months 
after the patient has responded (Montgomery, 
1994) Most authors also recommend that full 
doses of antidepressants should be used during 
this period (Frank et. a!., 1990), although some 
continuation phase of depression 
studies have suggested that lower doses might 
be as effective (Mindham et. al., 1973) The 
consensus view reflected by some of the current 
guidelines seems to be that, continuation doses 
should be no less than those used for acute 
treatment (American Psychiatric Association 
Work Group on Major Depressive Disorder, 1993; 
Clinical Resource Audit Group, 1993). 
These viewpoints though well known are 
often not translated into clinical practice There 
are several reports of inadequate treatment with 
antidepressants during the acute phase (Quitkin, 
1985). There are, however very few similar 
investigations of continuation treatment Case 
records of 4052 patients with a diagnosis of 
depression followed-up for 2 years were studied 
by Melfi et al (1998) in a recent investigation. 
They demonstrated that those patients who 
continued treatment for longer periods fared better 
in terms of recurrences and relapses In another 
retrospective study 102 patients who had 
recovered from an acute episode of depression 
were interviewed 18 months after discharge 
(Ramanaet al., 1999) Assessments of adequacy 
of treatment and patient compliance were maoe 
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monthly over this period. About 30% of the 
patients had failed to receive adequate long-term 
treatment Although deficiencies in treatment were 
greater inpatients who had not recovered fully, 
further episodes of depression were not 
particularly associated with inadequate treatment. 
A survey of adequacy of treatments in 
depression would be particularly useful in the 
Indian context where there is a marked variability 
in practice across different treatment settings, 
and a genuine need to establish minimum 
standards in all aspects of psychiatric care. This 
study was a part of larger exercise to ascertain 
the nature and adequacy of antidepressant 
treatment in a selected group of depressed 
patients. This paper deals with the nature of 
treatment in the continuation phase, focusing 
mainly on the type and doses of drugs used and 
the length of treatment. 
MATERIAL AND METHOD 
The study was carried out in the psychiatric 
unit of a large multi-speciality teaching institution 
(Nehru Hospital of the Postgraduate Institute of 
Medical Education and Research, Chandigarh). 
All patients attending the unit are initially screened 
by a psychiatrist at the Walk-in' clinic level, and 
drug treatment often started. Subsequently, a 
detailed evaluation is done by a trainee 
psychiatrist under supervision of a consultant. 
Treatment plans are charted out, and patients are 
then followed-up in the outpatient clinic, unless 
admitted, or referred elsewhere 
Case notes for the year 1996 were 
scanned for all cases of depression. Those, 
which fulfilled the selection criteria, were included 
for purposes of the study. The data pertaining to 
antidepressants was then extracted from the 
notes and entered onto the pre-set proforma. 
Selection criteria Cases were included if they were 
diagnosed to have either: depressive episodes of 
mild, moderate, or severe type; with or without 
somatic symptoms (ICD-10), or recurrent 
depressive disorder with similar current episodes. 
Cases were excluded if they had : bipolar 
depression, any comorbid diagnoses, psychotic 
symptoms, chronic episodes (>2 years), organic 
brain syndrome, substance abuse, associated 
physical problems judged to be interfering with 
antidepressant treatment & follow up period less 
than 6 weeks. 
A deliberate attempt was thus made to 
include relatively 'uncomplicated' cases of 
depression by excluding secondary depression, 
chronic episodes, and comorbid conditions. 
Although this restricted the scope oi the study, it 
was felt that proper judgements about adequacy 
of treatment could only be made after ruling out 
these confounding variables. 
A total of 108 such cases of depression 
were identified. Seventy of these had received 
continuation treatment after recovering from the 
acute episode. Data regarding various aspects 
of antidepressant treatment during the 
continuation phase were extracted from these 
70 case notes. 
The criteria for "adequacy' of treatment 
during the continuation phase were derived from 
standard guidelines and results of original studies. 
These have been included in the appendix. 
RESULTS 
Only results pertaining to the continuation 
phase treatment are presented here. 
Demographic and clinical profile: Majority of the 
sample was female (n=41; 59% ), most in the 
age range of 30 to 49 years ( 57%), with 17% 
below 30 years, and 26 % above 50 years. 
Average age of the sample was 42.23 (s.d. 
13.83) years. Fifty cases had a diagnosis of 
single depressive episode, 20 had recurrent 
depressive disorders. The commonest diagnosis 
for the index episode was moderate depression 
with or without somatic symptoms (n=40; 57%), 
followed by severe depression without psychotic 
symptoms (n=24; 34%). In summary, the sample 
comprised mainly of middle aged females with 
moderate depression 
Modes of treatment: Antidepressants were used 
in all cases. One case received three treatments 
of ECT over the first two weeks of the 
continuation phase, in combination with 
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antidepressants. Antidepressants were used 
singly in 61 cases, 9 cases received a 
combination of these drugs. In all cases, except 
one where drugs were switched (from Fluoxetine 
to Imipramine), antidepressant(s) used during the 
acute phase were continued during the 
continuation phase. TCAs were the most 
commonly used agents; 40 cases (57%) received 
a drug from this group either alone or in 
combination with others. Imipramine was the 
TCA most commonly used (n=26; 37%). 
However, Fluoxetine was used in 27 cases 
(39%), in eight of these an additional drug was 
TABLE -1 
MODES OF CONTINUATION TREATMENT 
1. Treatment with a single drug 
Type of drug (n = 62) 
Imipramine 
Dotheipin 
Nortriptyline 
Amitriptyline 
Cioimipramine 
Fluoxetine 
Mianserin 
Amoxapine 
24 
7 
3 
2 
1 
19 
4 
1 
2. Treatment with a combination of drugs 
Drug combination (n = 9) 
Fluoxetine & Trazodone 
Mianserin 8. Trazodone 
Fluoxetines Imipramine 
Fluoxetine & Nortriptyline 
Fluoxetine & Amoxapine 
4 
1 
2 
1 
1 
Total number of cases - 70; one patient received two drugs in 
succession 
One patient received ECT in addition to Imipramine 
TABLE -2 
DOSE OF ANTIDEPRESSANTS 
Dose range 
TCAs* (n = 40) 
Less than 150 mg/day 
150 mg/day & more 
Fluoxetine (n = 27) 
20 to 30 mg/day 
40 mg/day & more 
Mianserin (n = 5) 
Less than 30 mg/day 
30 mg/day & more 
No.of Cases 
25 
15 
16 
11 
3 
2 
* All TCA doses in Imipramine equivalents 
also used (table -1). 
Doses used/duration of treatment : TCAs were 
mostly used in doses less than 150 mg/day 
Imipramine equivalents. Twenty five patients (63%) 
received doses less than this, and only 15 patients 
received 150 mg/day or more. Most patients being 
treated with Fluoxetine received a dose of 20 - 30 
mg daily (n=16; 59% ), (table -2). 
Antidepressants were withdrawn in 8 cases 
during the continuation phase. One of these 
patients was discovered to be pregnant, the other 
had switched into hypomania. The reasons for 
stopping drugs in the rest were not clear. In 18 
cases the dose of the antidepressant was reduced 
during continuation treatment. None of these 
dose reductions could be attributed to onset of 
side effects, and thus remained inexplicable. 
Thus, although the majority of patients (n=44; 
63 %) had received doses similar to those used 
during acute phases of treatment, at least 24 
patients (34%) had their dose reduced- or drug 
withdrawn for unknown reasons (table-2). 
TABLE -3 
DOSAGE STRATEGIES DURING THE 
CONTINUATION PHASE 
Dose strategies 
Dose same as acute phase 
Dose reduced + 
Drug withdrawn * 
No. of cases 
( n = 70 ) 
44 
18 
8 
+ Reasons for reduction in dose in these patients not clear 
* Reasons for stopping drug in two patients was onset of 
pregnancy and hypomania respectively; in others reasons 
were unclear 
TABLE -4 
OUTCOME OVER SIX MONTHS 
Dose/out come* 'Well' 'Unwell' 
Same as acute phase 23 2 
Dose reduced or drug 
withdrawn 12 8 
-Total number of cases - 45; outcome unknown in 24, 
hypomania in one 
- Well - refers to patients who maintained well over a 6 
months 
- Unwell - refers to patients who had a deterioration in 
their mental state or relapsed during the 6 month period 
* X
2 = 4.86; df = 1; p < 0 05 (Yates correction applied) 
Outcome over six months : Twenty one cases 
had dropped out before six months, two had not 
completed six months of continuation therapy, 
one each had become hypomanic or pregnant. 
It was thus possible to make an approximate 
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judgement of the outcome over six months of 
continuation treatment in only 45 patients, who 
had followed up, for that duration. These patients 
had been seen about once every two months 
during this period (average number of visits -
2.67+ 1.49). 
Whenever the notes indicated that the 
patient had developed fresh depressive 
symptoms this was taken as a 'worsening' in 
patient's clinical state When the notes indicated 
that the patient had developed the full 
complement of depressive symptoms (sufficient 
to qualify for a depressive episode), this was 
taken as a relapse' For comparing outcome thse 
two categories were combined. 
The outcome data (table - 4) show that of 
these 35 patients had remained well during the 
continuation phase, whereas 10 had either 
deteriorated or relapsed completely. Table - 4 
also shows, that while only a small proportion of 
patients (9%) on full doses had a poor outcome, 
a much larger number of patients (67%), whose 
drugs were either stopped or doses reduced, had 
worsened or relapsed. These differences were 
statistically significant (x
2=4.86; df =1; p<0.05 ). 
DISCUSSION 
A case note study such as this has several 
limitations Incomplete records, lack of structured 
assessments, and the effect of confounding 
variables make interpretation of data difficult. 
Several tentative conclusions can nevertheless 
be made 
Regarding adequacy of continuation 
treatment, most patients had been continued on 
antidepressants for a period of six months, unless 
they had dropped out, or drugs had to be stopped 
for other reasons In a small minority drugs had 
been withdrawn for no apparent reason, and in 
a much larger proportion their dose had been 
reduced quite inexplicably Overall, more than 
a third of the patients (34%) had received 
continuation treatment that was inadequate with 
regard to doses or duration This is quite similar 
to the figure of 30% reported by Ramana et al. 
(1999), although their study was of a much longer 
duration. In this study cases which had received 
inadequate treatment were significantly more 
likely to have worsened or relapsed completely. 
In contrast, Ramana et al. (1999) had found 
inadequate treatment to be associated with non-
recovery, but not further recurrences. They had 
thus come to the conclusion that low levels of 
treatment were not associated with poor 
outcome The fact that cases with inadequate 
treatment had a poorer outcome in this study 
perhaps lends further credence to the 
recommendation that continuation treatment 
should continue for six months at full doses of 
antidepressants (Frank et al., 1990). 
The type of antidepressant treatment used 
during the continuation period is also of some 
interest. Not surprisingly drugs were used 
universally. Use of other modes such as ECT or 
mood stabilisers was uncommon or non-existent, 
perhaps partly due to the nature of the sample. 
In all cases except one the drug(s) used during 
the acute phase were continued. The commonly 
used drugs were Fluoxetine (the only SSRI 
available in India at the time of this study), and 
Imipramine. Although the efficacy of TCAs in 
long-term treatment is well established, data 
regarding SSRIs is still emerging (Montgomery, 
1994) However, this study shows that SSRIs are 
being used for this purpose in clinical situations. 
Actual doses of drugs used during the 
continuation phase are highly variable, perhaps 
a bit on the lower side, especially with regard to 
TCAs. This was observed in the acute phase of 
treatment as well, and is perhaps due to lower 
dose requirements of the Asian population as 
documented by some studies (Kuruvilla, 1986). 
However, without further dose- response studies, 
this will remain a mere speculation. 
In conclusion, this survey of continuation 
treatment reveals that although antidepressants 
are being used for this purpose, either doses or 
duration of treatment are inadequate in a 
substantial number of patients. This was despite 
the study being conducted in a teaching 
institution where concerted efforts are made to 
maintain minimum standards of care. The 
reasons for this 'treatment gap' between 
32 ANTIDEPRESSANT PRESCRIPTIONS : CONTINUATION PHASE TREATMENTS 
knowledge and practice need to be explored, 
since low levels of continuation treatment seem 
to be associated with poor outcome. It may thus 
be necessary to conduct prospective 
investigations of a similar nature to examine this 
association further. Such studies also need to 
be carried out in other settings (e.g. general 
practice) in India, to learn more about quality of 
treatment being received by patients with 
depression. Education of all clinicians about 
these central aspects of antidepressant 
treatment remains a priority. 
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APPENDIX 
CRITERIA FOR ADEQUATE' ANTIDEPRESSANT 
TREATMENT IN THE CONTINUATION PHASE + 
Dose 
Doses used during the continuation phase should be the 
same as the (full) doses used during the acute phase 
Duration 
Minimum of 6 months after the episode has remitted 
these criteria have been derived from the following -
American Psychiatric Association Work Group on Major 
Depressive Disorder. 1993: 
Clinical Resource and Audit Group, 1993; 
Frank etal., 1990 
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